CN Patent

CN102127054B — 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物

Assigned to Nanjing Cavendish Bio Engineering Technology Co Ltd · Expires 2013-04-03 · 13y expired

What this patent protects

本发明公开了3-(4-氨基-1-氧代-1，3-二氢-2H-异吲哚-2-基)哌啶-2，6-二酮的多晶型物，此外，本发明还公开了其制备方法和药物组合物。

USPTO Abstract

本发明公开了3-(4-氨基-1-氧代-1，3-二氢-2H-异吲哚-2-基)哌啶-2，6-二酮的多晶型物，此外，本发明还公开了其制备方法和药物组合物。

Drugs covered by this patent

Revlimid (lenalidomide) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN102127054B
Jurisdiction: CN
Classification: —
Expires: 2013-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Cavendish Bio Engineering Technology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.